Lancet commission proposes diagnosing clinical obesity by organ dysfunction, not BMI alone
The framework separates obesity with organ damage from obesity without it, and challenges coverage rules that tie treatment to a BMI cutoff plus another diagnosis.
A 58-member commission convened by the journal Lancet Diabetes & Endocrinology published a new framework on Jan. 14, 2025 that proposes diagnosing obesity through evidence of organ dysfunction rather than body mass index alone [1]. The report, endorsed by 76 organizations, appears in the journal's March 2025 issue [1].
The framework splits obesity into two categories. Clinical obesity is defined as a chronic, systemic illness with documented dysfunction of organs or tissues. Preclinical obesity is defined as excess body fat with preserved organ function [1]. The distinction is meant to separate people who are already ill because of excess fat from people who carry extra weight but do not yet show measurable harm.
On BMI, the commission takes a specific position: it should be used as a population-level screening tool, a way to flag groups for further evaluation, and not as an individual measure of health [1]. BMI is a ratio of weight to height and does not distinguish fat from muscle or show where fat is stored.
The report also addresses treatment and coverage. It argues that clinical obesity should not require a second, separate disease to justify treatment or reimbursement [1]. In effect, the commission says obesity itself — when organ dysfunction is documented — should be enough, without waiting for a diagnosis such as type 2 diabetes or high blood pressure to make the case.
The report is a consensus statement, not a regulation. It does not change what the US Food and Drug Administration has approved, and it does not by itself alter insurance policies. The paper also lists author affiliations that include industry roles; one commissioner is listed with International Medical Affairs at Eli Lilly [1].
Why it matters for patients
Most coverage decisions for GLP-1 medications such as Ozempic, Wegovy, Rybelsus (semaglutide), Mounjaro and Zepbound (tirzepatide) turn on eligibility rules, and those rules generally rely on BMI thresholds, often combined with at least one related condition. The commission's argument cuts against that structure [1].
If payers moved toward the framework, the practical effect would be a different set of questions: not only how much someone weighs, but whether tests show organ or tissue dysfunction tied to excess fat. That could matter to people whose BMI falls below a cutoff but who have measurable metabolic harm, and to people above a cutoff who do not.
Nothing about the framework is self-executing. It has not been reported that any US insurer, pharmacy benefit manager, employer plan or state Medicaid program has adopted the definitions, and the FDA has not announced any change to how it evaluates obesity treatments [1]. For now, existing coverage criteria remain the ones that govern who pays for what.
What happens next
The paper itself is published, with the March 2025 print issue following the Jan. 14 online release [1]. No timeline has been disclosed for how or whether US payers, professional societies or regulators will act on the definitions, and no organization has announced a date for reviewing them [1].
One open question the report does not resolve in the published text is how organ dysfunction would be measured in routine practice, or which specific tests would be required. The commission's full criteria and evidence review run from page 221 to page 262 of the journal issue [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.